- Zacks•6 days ago
The Medicines Company (MDCO) announced a new strategic partnership with the Biomedical Advanced Research and Development Authority under which the company will receive funding for developing of new infection drug.
- Accesswire•6 days agoBlog Coverage Medicines Company in a Strategic Partnership with BARDA to Develop a New Range of Antibiotics
LONDON, UK / ACCESSWIRE / September 22, 2016 / Active Wall St. blog coverage looks at the headline from The Medicines Company (NASDAQ: MDCO ) as the company announced on September 21, 2016, that the U.S. ...
- Reuters•7 days ago
The Medicines Co on Wednesday said it will receive up to $132 million in U.S. government funding for development of new antibiotics to fight drug-resistant infections, seen by health officials as a critically important need. Under terms of the agreement, the company said it will receive $32 million in initial funding from BARDA, the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services. Medicines Co would be eligible to receive up to an additional $100 million over five years if BARDA exercises all of its options to extend the partnership, the company said.
The Medicines Company (MDCO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||40.01 x 100|
|Ask||40.03 x 100|
|Day's Range||39.40 - 40.21|
|52wk Range||27.50 - 43.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-12.44|
|Avg Vol (3m)||847,215|
|Dividend & Yield||N/A (N/A)|